The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...

The FDA approved lebrikizumab (Ebglyss) for treating atopic dermatitis in adults and children ages 12 years and up, drugmaker ...

As more drugs approach late-stage development for PAH, Cereno Scientific’s CEO expects more successful disease-modifying ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months ... a GGG tri-agonist. Several phase III data readouts are ...

The FDA on Friday signed off on Eli Lilly ’s therapeutic antibody lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Lilly will market the therapy under the ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...

The broad indication in HR+/HER2- stage II and III EBC at high risk of recurrence approximately ... Last year, the FDA also ...